the newYou can now listen to Fox News articles!
A study recently published in the New England Journal of Medicine showed that taking diabetes medication once a week leads to significant weight loss in obese people. The study authors said that participants in the 72-week trial lost up to 20% of their body weight.
“The results suggest that terzepeptide may be a potential treatment option for obese individuals, with participants losing between 16% and 22.5% of their initial weight,” the study authors said.
The drug, tirzepatide, is a new drug recently approved by the Food and Drug Administration to help treat type 2 diabetes through a once-weekly injection. The drug works on two types of hormones that help control blood sugar and send signals of fullness to the brainAnd the The authors explained in the study. The investigators decided to look at the effect of a diabetes drug on obesity and presented the results of a phase III trial at a symposium at the 82nd Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Los Angeles.
Kim Kardashian’s strict diet may lead to weight gain: health experts
A phase 3 double-blind, randomized, controlled trial of 72 weeks duration included more than 2,500 participants who were obese and did not have diabetes.
The research team divided the participants into four groups. Three of the groups were given 5 mg, 10 mg or 15 mg of tirzepatide to be self-administered once a week for 72 weeks, while the fourth group was given a self-administering dummy injection. The four groups were given counseling sessions on lifestyle habits and low-calorie meals. They also performed at least 150 minutes of physical activity per week.
The researchers found that 89% of the participants, who took the 5 mg dose of the drug and 96% who took the 10 mg and 15 mg weekly dose of the drug, achieved a reduction of at least 5% in body weight compared to 28% of those. in the placebo group.
According to the report, participants who took the 5 mg dose of tirzepatide lost an average of 35 pounds, and the 10 mg group achieved a mean loss of 49 pounds. Participants who took the 15 mg injection experienced an average weight loss of 52 pounds over the 72 weeks of the study. Those in the second group achieved 5 lb-ft. Weight loss rate according to the study.
People lose weight because of health benefits, not physical appearance: Mayo Clinic survey
“Obesity must be treated like any other chronic disease — through effective and safe approaches that target the underlying disease mechanisms, and these findings confirm that terzepeptide may do just that,” lead researcher Anya Gastropov, MD, PhD, associate professor at Yale University School of Medicine said. And director of Weight Management and Obesity Prevention at the Yale Stress Center for a media outlet.
“These findings are an important step forward in expanding potentially effective treatment options for people who are obese. It should be noted that approximately 9 out of 10 obese individuals lost weight while taking terazipatide,” Gastripov, who is also the co-director of the Yale Center for Disease Control and Prevention, said. Weight management in Connecticut in a media report.
CLICK HERE FOR FOX NEWS APPLICATION
According to the Centers for Disease Control and Prevention (CDC), the prevalence of obesity in the United States was approximately 42% in 2017 through March 2020. The CDC stated that obesity-related diseases include heart disease, stroke, type 2 diabetes, and some types of cancer. .